Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients

INTRODUCTION: The antiviral drug favipiravir has been shown to have in vitro antiviral activity against severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2). In this study, we investigated the clinical benefits and initiation of favipiravir treatment in patients with non-severe coronavirus-d...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Infect Chemother
Главные авторы: Fujii, Satoshi, Ibe, Yuta, Ishigo, Tomoyuki, Inamura, Hirotoshi, Kunimoto, Yusuke, Fujiya, Yoshihiro, Kuronuma, Koji, Nakata, Hiromasa, Fukudo, Masahide, Takahashi, Satoshi
Формат: Artigo
Язык:Inglês
Опубликовано: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8052467/
https://ncbi.nlm.nih.gov/pubmed/33902990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jiac.2021.04.013
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы